• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    US Metabolic Biomarker Testing Market

    ID: MRFR/LS/11990-HCR
    100 Pages
    Garvit Vyas
    October 2025

    US Metabolic Biomarker Testing Market Research Report: By Techniques (Separation techniques, Detection techniques), By Indication (Cancer, Cardiovascular disorders, Neurological disorders, Inborn errors of metabolism, Others), By Application (Drug discovery or drug assessment, Nutrigenomics, Toxicology testing, Personalized medicine, Functional genomics, Others) and By End User (Pharma & biotech companies, Diagnostic tool companies, Healthcare IT/big data companies, Clinical laboratories, Others) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Metabolic Biomarker Testing Market Infographic
    Purchase Options
    Compare License
    Summary Table of Contents Segmentation Download PDF

    US Metabolic Biomarker Testing Market Summary

    The US Metabolic Biomarker Testing market is poised for substantial growth, projected to reach 1363.7 USD Million by 2035.

    Key Market Trends & Highlights

    US Metabolic Biomarker Testing Key Trends and Highlights

    • The market valuation is expected to grow from 588.8 USD Million in 2024 to 1363.7 USD Million by 2035.
    • The compound annual growth rate (CAGR) for the period between 2025 and 2035 is estimated at 7.93%.
    • This growth trajectory indicates a robust demand for metabolic biomarker testing services in the United States.
    • Growing adoption of advanced diagnostic technologies due to increasing prevalence of metabolic disorders is a major market driver.

    Market Size & Forecast

    2024 Market Size 588.8 (USD Million)
    2035 Market Size 1363.7 (USD Million)
    CAGR (2025-2035) 7.93%

    Major Players

    Illumina, Laboratory Corporation of America, Roche Diagnostics, BioRad Laboratories, Fulgent Genetics, Precision Biomarker Solutions, Vitagene, Abbott Laboratories, Genetic Technologies, Thermo Fisher Scientific, GenoPalate, Quest Diagnostics, Siemens Healthineers, Eurofins Scientific

    US Metabolic Biomarker Testing Market Trends

    The US Metabolic Biomarker Testing Market is reflecting notable growth driven by several key market drivers. The increasing prevalence of metabolic disorders, such as obesity and diabetes, is prompting a demand for efficient testing solutions. This trend is supported by government initiatives aimed at promoting preventive healthcare and early diagnosis, particularly through programs such as the National Diabetes Prevention Program.

    Enhanced awareness among patients and healthcare providers about the importance of metabolic health is also significantly driving the market. Additionally, opportunities to be explored include the rise of personalized medicine and the integration of advanced technologies in testing processes.The use of AI and machine learning in data analysis is providing healthcare professionals with precise insights into individual metabolic conditions.

    This presents an opportunity for companies to develop innovative and accurate testing methodologies that cater to individualized patient needs. In recent times, there has been a noticeable trend towards the incorporation of at-home testing kits and point-of-care testing solutions. These innovations are designed to enhance patient engagement and facilitate easier access to testing.

    Legislative support for remote healthcare services, particularly after the COVID-19 pandemic, has further accelerated this trend, as patients are more inclined towards convenient testing options.The ongoing research and development in the field of metabolic biomarkers are also paving the way for new test types, contributing to the overall advancement of the market in the US.

    Market Segment Insights

    Metabolic Biomarker Testing Market Techniques Insights

    The Techniques segment within the US Metabolic Biomarker Testing Market demonstrates a prominent and evolving landscape, driven by an increasing need for personalized medicine and precision health solutions. As organizations in the healthcare sector seek efficient and reliable methods to diagnose and monitor metabolic disorders, the use of advanced Techniques becomes more crucial. This segment can largely be categorized into two primary domains Separation techniques and Detection techniques.

    Separation techniques have gained significant traction due to their ability to effectively isolate biomolecules from complex biological samples, enabling researchers to obtain precise measurements. This capability is especially important as the complexity of biological matrices poses challenges in biomarker quantification. Meanwhile, Detection techniques play an equally critical role by enabling the identification and quantification of specific biomarkers with high sensitivity and specificity.

    These techniques are essential for ensuring accurate diagnoses, monitoring disease progression, and evaluating response to therapies.The demand for these Techniques is further propelled by technological advancements in instrumentation and assay development, leading to more reliable outcomes in metabolic testing. The growing prevalence of metabolic diseases, such as diabetes and cardiovascular disorders, alongside the rise in healthcare expenditure within the United States has resulted in amplified investment in these Testing Techniques.

    Both aforementioned techniques are not only integral for diagnostic purposes but also contribute to ongoing Research and Development activities aimed at discovering novel metabolic markers to enhance patient care.In the competitive landscape of the US Metabolic Biomarker Testing Market, organizations are focusing on the refinement of existing Techniques while exploring innovative approaches to develop new biomarker tests. This trend is being bolstered by successful collaborations between academic institutions and biotech firms to accelerate the translation of research findings into clinical applications.

    Additionally, a rich pool of funding opportunities from both public and private sectors fuels the expansion of Techniques used in this market segment, thus driving overall growth. Market trends also reflect a growing emphasis on non-invasive techniques, which are anticipated to enhance patient compliance and yield reliable data. In summary, the Techniques segment of the US Metabolic Biomarker Testing Market plays a vital role in advancing the field of personalized medicine, enabling healthcare providers to deliver tailored treatment plans that align with individual patient needs.

    Metabolic Biomarker Testing Market Indication Insights

    The US Metabolic Biomarker Testing Market is characterized by its diverse range of indications, which play a crucial role in enhancing disease diagnosis and management. Among these, cancer is a prominent segment due to the rising incidence of various cancer types, emphasizing the demand for effective early detection and targeted therapies. Cardiovascular disorders also represent a significant portion of the market, driven by the increasing prevalence of heart diseases and the need for timely intervention through precise biomarker testing.

    Neurological disorders are gaining attention as advancements in biomarker research pioneer new approaches for conditions such as Alzheimer's and Parkinson's diseases, leading to improved patient outcomes.Inborn errors of metabolism encompass a variety of genetic metabolic disorders, highlighting the importance of metabolic profiling in newborn screening programs across the US, thus facilitating early identification and management. Additional indications covered by the market include other metabolic disorders, showcasing a broad spectrum of applications that cater to evolving healthcare needs.

    Overall, the significance of these indications underscores the growing emphasis on precision medicine and patient-centered approaches within the US healthcare landscape, demonstrating their impact on clinical decision-making and treatment strategies.

    Metabolic Biomarker Testing Market Application Insights

    The Application segment of the US Metabolic Biomarker Testing Market plays a pivotal role in advancing healthcare innovations and personalized medicine approaches. Within this segment, Drug discovery or drug assessment stands out for its essential role in streamlining the development of new therapies, leading to faster and more effective treatments reaching patients. Nutrigenomics focuses on the genetic influence of diet, thereby guiding personalized nutrition strategies, which is gaining attention as the population increasingly seeks tailored health solutions.

    Toxicology testing is crucial for ensuring the safety of new pharmaceuticals and consumer products, thereby protecting public health. Personalized medicine, leveraging genetic and metabolic data, aims to customize healthcare, enhancing treatment outcomes by targeting specific patient needs, which continues to see substantial investment from biotech firms. Furthermore, Functional genomics provides insights into gene functions and interactions, which is vital for understanding metabolic processes in disease.

    Each of these areas presents significant growth potential, driven by advancements in technology and increasing demand for personalized health solutions across the United States, ultimately shaping the future landscape of the healthcare industry.

    Metabolic Biomarker Testing Market End User Insights

    The US Metabolic Biomarker Testing Market has a diverse range of end users, which significantly influences its growth and dynamics. Dominating the landscape are pharma and biotech companies that leverage metabolic biomarkers for drug development and personalized medicine, facilitating more efficient clinical trials and enhancing treatment outcomes. Diagnostic tool companies play a critical role as well, as they develop advanced testing solutions that enable early disease detection and monitoring, thereby impacting patient management.

    Meanwhile, healthcare IT and big data companies contribute vital infrastructure and analytical capabilities that optimize the use of metabolic data, driving innovation in the sector.Clinical laboratories are essential for processing tests and providing accurate results, supporting both healthcare providers and patients. The presence of these end users creates a robust ecosystem that fosters continuous advancements in metabolic biomarker testing, ultimately enhancing the overall efficiency and effectiveness of the healthcare system in the United States.

    As trends evolve, these segments are poised to capitalize on emerging technologies, regulatory support, and an increasing focus on preventive healthcare, thus propelling the market forward.

    Get more detailed insights about US Metabolic Biomarker Testing Market
    Request Free Sample

    Key Players and Competitive Insights

    The US Metabolic Biomarker Testing Market is characterized by a diverse landscape of players that collectively contribute to a rapidly evolving ecosystem. This market focuses on technological advancements in molecular diagnostics and personalized medicine, which have become increasingly crucial as healthcare emphasizes preventive measures and tailored treatments. The demand for metabolic biomarker tests is primarily driven by factors such as the rise of chronic diseases, increasing healthcare expenditures, and an expanding emphasis on patient-centered approaches.

    Companies within this market are continuously innovating to provide efficient and accurate testing solutions while navigating complex regulatory environments and competitive pressures. Competitive dynamics are shaped by collaborations, partnerships, and mergers that aim to enhance product offerings, improve service delivery, and expand market reach, indicating a highly interwoven network of stakeholders focused on delivering cutting-edge healthcare solutions.

    Illumina

    Illumina is a prominent player in the US Metabolic Biomarker Testing Market, known for its advanced sequencing technology and genomic solutions. The company benefits from a strong portfolio that supports various testing applications, particularly those that serve the burgeoning field of personalized medicine. Illumina's scalable platforms facilitate high-throughput sequencing, which is integral for metabolic profiling and biomarker identification.

    Additionally, Illumina's strategic focus on innovation and research allows it to maintain a competitive edge in genetic testing and data analysis. Their commitment to advancing technology, alongside a robust customer support system, enhances client satisfaction and fosters long-term partnerships within the healthcare ecosystem. Furthermore, Illumina's collaborations with academic institutions and healthcare providers strengthen their position in the market, enabling them to drive advancements in metabolic biomarker testing.

    Laboratory Corporation of America

    Laboratory Corporation of America is a key player in the US Metabolic Biomarker Testing Market, offering a wide range of diagnostic services that are critical for monitoring and understanding metabolic disorders. The company’s extensive network of laboratories and its capabilities in customizable testing facilitate timely and accurate results, making it a go-to choice for healthcare providers. Laboratory Corporation of America emphasizes quality assurance and compliance, which solidifies its reputation for reliability in diagnostic testing.

    They offer key products and services related to metabolic biomarkers, such as comprehensive panels that aid clinical decision-making. In recent years, the company has engaged in strategic mergers and acquisitions to expand its testing capabilities and strengthen its market presence, further enhancing their service offerings. The combination of Laboratory Corporation of America's technological investment, broad array of metabolic testing services, and commitment to enhancing patient care ensures they remain a formidable competitor in the landscape of metabolic biomarker testing within the US.

    Key Companies in the US Metabolic Biomarker Testing Market market include

    Industry Developments

    Recent developments in the US Metabolic Biomarker Testing Market have been characterized by significant advancements and corporate activities. Companies such as Illumina and Roche Diagnostics have increased their focus on Research and Development to enhance the precision of metabolic biomarker tests. Laboratory Corporation of America has reported a rise in demand for its testing services, particularly among chronic disease management programs.

    In September 2023, Abbott Laboratories announced the launch of a new suite of biomarkers aimed at identifying cardiovascular risks, reflecting ongoing innovation in the sector. Additionally, in August 2023, Quest Diagnostics acquired a diagnostics laboratory specializing in metabolic testing, further consolidating its market position. Growth in the valuation of companies like Thermo Fisher Scientific has been notable, driven by the increasing integration of metabolic biomarker testing in personalized medicine.

    Over the past few years, from 2021 to 2023, the market has seen more healthcare providers adopting metabolic biomarker testing as part of routine health assessments, responding to the rising prevalence of metabolic disorders in the US. This shift is helping to drive further investments and partnerships among key players like Siemens Healthineers and BioRad Laboratories.

    Market Segmentation

    Metabolic Biomarker Testing Market End User Outlook

    • Pharma & biotech companies
    • Diagnostic tool companies
    • Healthcare IT/big data companies
    • Clinical laboratories
    • Others

    Metabolic Biomarker Testing Market Indication Outlook

    • Cancer
    • Cardiovascular disorders
    • Neurological disorders
    • Inborn errors of metabolism
    • Others

    Metabolic Biomarker Testing Market Techniques Outlook

    • Separation techniques
    • Detection techniques

    Metabolic Biomarker Testing Market Application Outlook

    • Drug discovery or drug assessment
    • Nutrigenomics
    • Toxicology testing
    • Personalized medicine
    • Functional genomics
    • Others

    Report Scope

    Report Scope:
    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 569.6(USD Million)
    MARKET SIZE 2024 588.8(USD Million)
    MARKET SIZE 2035 1363.7(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 7.934% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Illumina, Laboratory Corporation of America, Roche Diagnostics, BioRad Laboratories, Fulgent Genetics, Precision Biomarker Solutions, Vitagene, Abbott Laboratories, Genetic Technologies, Thermo Fisher Scientific, GenoPalate, Quest Diagnostics, Siemens Healthineers, Eurofins Scientific
    SEGMENTS COVERED Techniques, Indication, Application, End User
    KEY MARKET OPPORTUNITIES Personalized medicine advancements, Rising prevalence of metabolic disorders, Integration with wearable technology, Increased government funding for research, Growth in preventive healthcare initiatives
    KEY MARKET DYNAMICS rising chronic disease prevalence, increasing health awareness, advancements in testing technology, personalized medicine trend, regulatory support and compliance
    COUNTRIES COVERED US

    FAQs

    What is the expected market size of the US Metabolic Biomarker Testing Market in 2024?

    The US Metabolic Biomarker Testing Market is expected to be valued at 588.8 million USD in 2024.

    What will the market valuation of the US Metabolic Biomarker Testing Market be by 2035?

    By 2035, the market valuation is projected to reach approximately 1363.7 million USD.

    What is the expected compound annual growth rate (CAGR) for the US Metabolic Biomarker Testing Market from 2025 to 2035?

    The expected CAGR for the US Metabolic Biomarker Testing Market from 2025 to 2035 is 7.934 percent.

    Which techniques have significant market shares in the US Metabolic Biomarker Testing Market?

    Separation techniques are valued at 220.0 million USD in 2024, while detection techniques hold a market value of 368.8 million USD in the same year.

    What will be the market size of separation techniques in 2035?

    The market size for separation techniques is projected to rise to 510.0 million USD by 2035.

    How much will the detection techniques market be valued in 2035?

    The detection techniques market is expected to grow to 853.7 million USD by 2035.

    Who are the major players in the US Metabolic Biomarker Testing Market?

    Key players include Illumina, Laboratory Corporation of America, Roche Diagnostics, and Thermo Fisher Scientific.

    What are the growth drivers for the US Metabolic Biomarker Testing Market?

    The growth is driven by advancements in technology and increasing demand for personalized medicine.

    Are there any emerging trends impacting the US Metabolic Biomarker Testing Market?

    Emerging trends include the integration of artificial intelligence and machine learning in biomarker analysis.

    What are some challenges faced by the US Metabolic Biomarker Testing Market?

    Challenges include regulatory hurdles and the need for standardized testing protocols across the industry.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Stories
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027